Previous 10 | Next 10 |
Sierra Oncology (SRRA): Q4 GAAP EPS of -$1.63 misses by $0.11.Revenue of $0.2MPress Release For further details see: Sierra Oncology EPS misses by $0.11
Sierra Oncology Reports 2020 Year End Results PR Newswire – MOMENTUM Phase 3 Trial on Track to Complete Enrollment in mid-2021 with Top-line Data Anticipated in H1 2022 – – Data Presented Throughout the Year Included Long-Term Overall Surviva...
Sierra Oncology to Present at Three Upcoming Investor Conferences PR Newswire —HC Wainwright Life Sciences Conference beginning at 7:00 am ET on March 9th— —Roth Conference at 10:00 am ET on March 15 th — —...
Sierra Oncology Announces Presentation at LifeSci Partners Precision Oncology Day PR Newswire SAN MATEO, Calif. , Feb. 12, 2021 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat...
For all practical purposes, Sierra Oncology today is a single product company, solely focused on its most advanced product, momelotinib, which is targeted at Myelofibrosis. There will likely be easier times ahead, which will allow investors to take calls on the company’s stock ...
Sierra Oncology to Present at H.C. Wainwright 2021 BioConnect Virtual Conference Canada NewsWire VANCOUVER, BC , Jan. 5, 2021 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rar...
H.C. Wainwright resumes coverage on Sierra Oncology (SRRA) with a ‘Buy’ rating. The price target of $29 is almost double the stock’s yesterday’s close.The analyst, Joseph Pantginis notes “Sierra is in a strong position to deliver a differentiated drug for th...
Nano-cap Sierra Oncology ([[SRRA]] +1.7%) has updated overall survival ((OS)) data for momelotinib from Phase 3 studies in myelofibrosis patients, both JAKi-naïve and previously treated with ruxolitinib. Data were presented at the American Society of Hematology.SIMPLIFY-1 (S1) ...
Sierra Oncology Announces Momelotinib Data for Intermediate / High-risk Myelofibrosis Patients with Lower Baseline Platelet Counts --Retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate safety and activity profile are not impacted by baseline platelet count-- ...
Sierra Oncology Presents Long-term Overall Survival and Sustained Efficacy Outcomes Data for Momelotinib at ASH Annual Meeting --Momelotinib demonstrates robust overall survival in both JAKi-naïve and patients previously treated with ruxolitinib-- VANCOUVER, BC ...
News, Short Squeeze, Breakout and More Instantly...
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading en...
– Submission seeks approval of momelotinib for the treatment of myelofibrosis – Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced the company has submi...